vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.

Local Bounti Corporation is the larger business by last-quarter revenue ($12.5M vs $11.0M, roughly 1.1× C4 Therapeutics, Inc.). Local Bounti Corporation runs the higher net margin — -69.8% vs -186.0%, a 116.1% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 23.7%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 21.9%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.

CCCC vs LOCL — Head-to-Head

Bigger by revenue
LOCL
LOCL
1.1× larger
LOCL
$12.5M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+89.1% gap
CCCC
112.8%
23.7%
LOCL
Higher net margin
LOCL
LOCL
116.1% more per $
LOCL
-69.8%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
21.9%
LOCL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
LOCL
LOCL
Revenue
$11.0M
$12.5M
Net Profit
$-20.5M
$-8.7M
Gross Margin
12.2%
Operating Margin
-210.1%
-106.1%
Net Margin
-186.0%
-69.8%
Revenue YoY
112.8%
23.7%
Net Profit YoY
40.7%
76.0%
EPS (diluted)
$-0.09
$1.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
LOCL
LOCL
Q4 25
$11.0M
$12.5M
Q3 25
$11.2M
$12.2M
Q2 25
$6.5M
$12.1M
Q1 25
$7.2M
$11.6M
Q4 24
$5.2M
$10.1M
Q3 24
$15.4M
$10.2M
Q2 24
$12.0M
$9.4M
Q1 24
$3.0M
$8.4M
Net Profit
CCCC
CCCC
LOCL
LOCL
Q4 25
$-20.5M
$-8.7M
Q3 25
$-32.2M
$-26.4M
Q2 25
$-26.0M
$-21.6M
Q1 25
$-26.3M
$-37.7M
Q4 24
$-34.6M
$-36.3M
Q3 24
$-24.7M
$-34.3M
Q2 24
$-17.7M
$-25.3M
Q1 24
$-28.4M
$-24.1M
Gross Margin
CCCC
CCCC
LOCL
LOCL
Q4 25
12.2%
Q3 25
11.5%
Q2 25
12.2%
Q1 25
12.6%
Q4 24
5.4%
Q3 24
13.8%
Q2 24
14.3%
Q1 24
9.4%
Operating Margin
CCCC
CCCC
LOCL
LOCL
Q4 25
-210.1%
-106.1%
Q3 25
-306.4%
-149.4%
Q2 25
-441.0%
-127.7%
Q1 25
-402.9%
-135.6%
Q4 24
-728.4%
-166.6%
Q3 24
-183.9%
-176.0%
Q2 24
-178.6%
-146.8%
Q1 24
-1060.2%
-122.9%
Net Margin
CCCC
CCCC
LOCL
LOCL
Q4 25
-186.0%
-69.8%
Q3 25
-286.4%
-216.6%
Q2 25
-402.6%
-178.3%
Q1 25
-363.7%
-324.6%
Q4 24
-667.8%
-360.1%
Q3 24
-160.6%
-335.2%
Q2 24
-147.6%
-267.6%
Q1 24
-933.2%
-286.9%
EPS (diluted)
CCCC
CCCC
LOCL
LOCL
Q4 25
$-0.09
$1.52
Q3 25
$-0.44
$-1.18
Q2 25
$-0.37
$-1.63
Q1 25
$-0.37
$-4.32
Q4 24
$-0.50
$-4.24
Q3 24
$-0.35
$-4.01
Q2 24
$-0.26
$-3.00
Q1 24
$-0.41
$-2.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
LOCL
LOCL
Cash + ST InvestmentsLiquidity on hand
$74.6M
$4.2M
Total DebtLower is stronger
$483.1M
Stockholders' EquityBook value
$256.6M
$-166.2M
Total Assets
$359.1M
$410.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
LOCL
LOCL
Q4 25
$74.6M
$4.2M
Q3 25
$58.8M
$6.2M
Q2 25
$78.2M
$5.3M
Q1 25
$51.3M
$18.0M
Q4 24
$55.5M
$937.0K
Q3 24
$59.6M
$317.0K
Q2 24
$73.1M
$9.7M
Q1 24
$89.7M
$8.2M
Total Debt
CCCC
CCCC
LOCL
LOCL
Q4 25
$483.1M
Q3 25
$484.9M
Q2 25
$478.3M
Q1 25
$480.0M
Q4 24
$436.8M
Q3 24
$398.4M
Q2 24
$374.0M
Q1 24
$329.8M
Stockholders' Equity
CCCC
CCCC
LOCL
LOCL
Q4 25
$256.6M
$-166.2M
Q3 25
$154.4M
$-158.1M
Q2 25
$174.1M
$-132.7M
Q1 25
$195.1M
$-134.5M
Q4 24
$216.0M
$-100.5M
Q3 24
$242.7M
$-65.6M
Q2 24
$247.1M
$-32.8M
Q1 24
$258.3M
$-9.4M
Total Assets
CCCC
CCCC
LOCL
LOCL
Q4 25
$359.1M
$410.5M
Q3 25
$265.5M
$417.8M
Q2 25
$296.5M
$426.8M
Q1 25
$319.5M
$447.2M
Q4 24
$349.6M
$428.0M
Q3 24
$376.1M
$430.8M
Q2 24
$381.1M
$438.1M
Q1 24
$398.4M
$413.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
LOCL
LOCL
Operating Cash FlowLast quarter
$-22.1M
$-3.1M
Free Cash FlowOCF − Capex
$-3.6M
FCF MarginFCF / Revenue
-29.1%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
LOCL
LOCL
Q4 25
$-22.1M
$-3.1M
Q3 25
$-31.2M
$-8.9M
Q2 25
$-12.1M
$-8.7M
Q1 25
$-33.3M
$-9.6M
Q4 24
$-17.9M
$1.2M
Q3 24
$-24.1M
$-17.2M
Q2 24
$-5.0M
$-4.0M
Q1 24
$-18.1M
$-7.1M
Free Cash Flow
CCCC
CCCC
LOCL
LOCL
Q4 25
$-3.6M
Q3 25
$-31.6M
$-10.1M
Q2 25
$-14.6M
Q1 25
$-14.5M
Q4 24
$-17.9M
$-8.6M
Q3 24
$-24.1M
$-30.0M
Q2 24
$-5.2M
$-28.8M
Q1 24
$-42.1M
FCF Margin
CCCC
CCCC
LOCL
LOCL
Q4 25
-29.1%
Q3 25
-281.5%
-82.8%
Q2 25
-121.0%
Q1 25
-125.1%
Q4 24
-346.5%
-85.3%
Q3 24
-157.2%
-293.1%
Q2 24
-43.1%
-305.4%
Q1 24
-501.8%
Capex Intensity
CCCC
CCCC
LOCL
LOCL
Q4 25
3.9%
Q3 25
3.7%
9.7%
Q2 25
48.9%
Q1 25
42.8%
Q4 24
0.1%
97.6%
Q3 24
0.1%
125.0%
Q2 24
1.6%
263.0%
Q1 24
0.0%
417.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons